Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Express Pharma
Hikal’s Bengaluru API facility receives Swissmedic GMP certification
The certification follows inspections by Brazil’s ANVISA and Japan’s PMDA, supporting Hikal’s expansion across regulated pharma markets The post Hikal’s Bengaluru API facility receives Swissmedic GMP certification appeared first on Express Pharma.
Read Full Article
Express Pharma
AIIA launches national AI challenge for Ayurveda on incubation centre’s sixth Foundation Day
AIIA-iCAINE launches an IPR facility, signs two MoUs with the World Ayurveda Foundation and Reliance Retail, and conducts a workshop on entrepreneurship and design thinking. The post AIIA launches national AI challenge for Ayurveda on incubation centre’s sixth Foundation Day appeared first on Express Pharma.
Read Full Article
Express Pharma
Our ambition is to be a trusted partner at each stage of that journey
Payal Agrawal, MD - India & South Asia, PerkinElmer India & South Asia, discusses the evolving analytical needs of India’s pharmaceutical industry, PerkinElmer’s LC-MS/MS offering and the role of advanced technologies, application expertise and laboratory services in supporting pharma R&D and quality testing, in an exclusive interview with Express Pharma The post Our ambition is to be a trusted partner at each stage of that journey appeared first on Express Pharma.
Read Full Article
Pharma Tech
RFK Jr backs compounding of six unapproved peptides in new policy
The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.
Read Full Article
Pharma Tech
Gaelic Labs: the EU Critical Medicines Act will have a positive impact on supply
Gaelic Labs is eyeing competitive benefits from its 2025 acquisition of fellow Irish beta-lactams manufacturer and further expansion.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Oct 30, 2026, 8:33 AM
BioMarin Licenses GC Biopharma and Hanmi Pharm’s HM15421/GC1134A for Fabry Disease in a ~$475M Deal
Shots: BioMarin has entered into an exclusive worldwide (ex-Korea) license agreement with GC Biopharma & Hanmi Pharm to develop & commercialize HM15421/GC1134A, an investigational long-acting SC enzyme replacement therapy for Fabry disease GC & Hanmi will receive $70M upfront and are jointly eligible for up to $405M in development & commercial milestones, plus tiered royalties… The post BioMarin Licenses GC Biopharma and Hanmi Pharm’s HM15421/GC1134A for Fabry Disease in a ~$475M Deal appeared first on PharmaShots.
PharmaShots
Oct 30, 2026, 8:32 AM
Instylla Receives the US FDA’s Approval for Expanded Indication of Embrace Hydrogel Embolic System to Treat Peripheral Arterial Bleeds
Shots: The US FDA has approved the expanded indication of Instylla’s Embrace Hydrogel Embolic System (HES) to include embolization of peripheral arterial bleeds in vessels ≤6mm, following its initial PMA in Aug 2025 for hypervascular tumor embolization Approval was based on the HALT study in 130 patients with peripheral arterial bleeds across 22 US sites,… The post Instylla Receives the US FDA’s Approval for Expanded Indication of Embrace Hydrogel Embolic System to Treat Peripheral Arterial Bleeds appeared first on PharmaShots.
PharmaShots
Oct 30, 2026, 8:29 AM
Iovance Reports Updated P-II (IOV-LUN-202) Trial Data of Lifileucel for Non-Squamous Metastatic NSCLC
Shots: Iovance has reported updated data from Cohorts 1 & 2 of the P-II (IOV-LUN-202) trial evaluating lifileucel in 69 patients with non-squamous mNSCLC that progressed on or after platinum-based CT & ICI therapy As of Oct 14, 2026, ORR was 24.6% (17/69), consistent with the previously reported 25.6%; ORR was 43.3% in KRAS wild-type… The post Iovance Reports Updated P-II (IOV-LUN-202) Trial Data of Lifileucel for Non-Squamous Metastatic NSCLC appeared first on PharmaShots.
PharmaShots
Oct 30, 2026, 8:26 AM
The EMA Validates Daiichi Sankyo’s MAAs for Single-Pill Triple Combinations of Bempedoic Acid + Ezetimibe + Statin for Hypercholesterolemia
Shots: The EMA has validated 2 MAAs from Daiichi Sankyo for oral, single-pill triple combinations of bempedoic acid + ezetimibe with either atorvastatin or rosuvastatin to treat adults with primary hypercholesterolemia or mixed dyslipidemia The therapies aim to reduce LDL-C levels & CV risk; multiple statin dose options of each combination are intended to offer… The post The EMA Validates Daiichi Sankyo’s MAAs for Single-Pill Triple Combinations of Bempedoic Acid + Ezetimibe + Statin for Hypercholesterolemia appeared first on PharmaShots.
PharmaShots
Oct 30, 2026, 8:22 AM
Eloxx Pharmaceuticals Receives the US FDA’s IND Clearance for Exaluren to Treat Nonsense-Mutation ADPKD
Shots: The US FDA has cleared Eloxx Pharmaceuticals’ IND for exaluren, an oral small-molecule ribosomal modulator, to treat nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD), enabling the P-II EXPRESS trial to open US sites The global P-II EXPRESS trial will randomize ~60 adults with PKD1 or PKD2 nonsense mutations (1:1) to exaluren or PBO for… The post Eloxx Pharmaceuticals Receives the US FDA’s IND Clearance for Exaluren to Treat Nonsense-Mutation ADPKD appeared first on PharmaShots.
PharmaShots
Oct 30, 2026, 8:05 AM
Bristol Myers Squibb Discontinues Development of Prothena-Partnered PRX019 and Terminates License Agreement
Shots: Bristol Myers Squibb has decided not to advance PRX019 (BMS-986495) further in the clinic following an internal strategic review, as disclosed by Prothena in an SEC filing; the PRX019 global license agreement will terminate on Jan 28, 2027 BMS licensed exclusive global rights to PRX019 in May 2024 for $80M upfront; with the termination,… The post Bristol Myers Squibb Discontinues Development of Prothena-Partnered PRX019 and Terminates License Agreement appeared first on PharmaShots.
News
Latest industry coverage
Google News
Oct 30, 2026, 8:34 AM
Orbis and AlzeCure change CEOs; Simris hires another Heidelberg Pharma veteran - European Biotechnology Magazine
Orbis and AlzeCure change CEOs; Simris hires another Heidelberg Pharma veteran European Biotechnology Magazine
Google News
Oct 30, 2026, 8:07 AM
Global pharma giants to showcase cutting-edge innovations at 9th CIIE - China Daily
Global pharma giants to showcase cutting-edge innovations at 9th CIIE China Daily
Google News
Oct 30, 2026, 7:59 AM
Senores Pharmaceuticals Plans ₹43 Crore Capacity Expansion Across US and India, Adds Prefilled Syringe Line - eHealth Magazine
Senores Pharmaceuticals Plans ₹43 Crore Capacity Expansion Across US and India, Adds Prefilled Syringe Line eHealth Magazine
Google News
Oct 30, 2026, 7:27 AM
Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff - Fierce Biotech
Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff Fierce Biotech
Google News
Oct 30, 2026, 7:22 AM
EDX Medical Appoints Biotech Industry Veteran Professor Michael Owen As Chairman - DirectorsTalk Interviews
EDX Medical Appoints Biotech Industry Veteran Professor Michael Owen As Chairman DirectorsTalk Interviews
Google News
Oct 30, 2026, 7:18 AM
How homegrown drugmaker Eris took on pharma giants in India’s semaglutide race - Moneycontrol.com
How homegrown drugmaker Eris took on pharma giants in India’s semaglutide race Moneycontrol.com
Google News
Oct 30, 2026, 7:04 AM
Navigating geopolitical risks: Practical and legal mitigations for the pharmaceutical industry - pharmaphorum
Navigating geopolitical risks: Practical and legal mitigations for the pharmaceutical industry pharmaphorum
Google News
Oct 30, 2026, 6:59 AM
Sanofi lifts expectations for 2026 sales growth, looks to M&A - Reuters
Sanofi lifts expectations for 2026 sales growth, looks to M&A Reuters
Google News
Oct 30, 2026, 6:40 AM
New deputy chief of China's SAMR meets with platforms, auto and drug companies - MLex
New deputy chief of China's SAMR meets with platforms, auto and drug companies MLex
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer